Riskpilot← Back to searchSign inGet full accessPRE CHINA HCV AS
ASActiveOrg 997694805Lilleakerveien 31, 0283 OsloActivities of financing conduits · NACE 6422Est. 20110 employees
Revenue 2024
NOK 0
EBITDA margin
—
-115% vs 2023
Equity ratio
0.3%
Financial strength
Net profit 2024
NOK -2,7M
-26% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -198K | -115% |
| Net profit | NOK -2,7M | -26% |
| Total assets | NOK 36M | +1% |
| Equity | NOK 100K | +0% |
| Employees | 0 | — |
Legal name
PRE CHINA HCV AS
Org number
997694805
Legal form
Aksjeselskap
NACE code
6422 · Activities of financing conduits
Founded
7. desember 2011
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Investere i det kinesiske private equity-fondet hony capital fund v, l.p., og alt som står i forbindelse med dette.
Address
Lilleakerveien 31, 0283 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −47 | −159 | −126 | −92 | −198 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −47 | −159 | −126 | −92 | −198 |
| Net financials | −2 687 | −1 355 | −2 341 | −2 764 | −2 666 |
| Profit before tax | −2 733 | −1 514 | −2 468 | −2 856 | −2 865 |
| Tax | 1 543 | −333 | 63 | −728 | −184 |
| Net profit | −4 277 | −1 181 | −2 531 | −2 128 | −2 681 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 68 258 | 51 322 | 49 328 | 35 700 | 35 954 |
| Equity | 92 | 92 | 100 | 100 | 100 |
| Long-term debt | 67 340 | 51 124 | 48 971 | 35 581 | 35 849 |
| Short-term debt | 826 | 106 | 257 | 19 | 5 |
| Total debt | 68 166 | 51 230 | 49 228 | 35 600 | 35 854 |
EBITDA margin
-19816700.0%
This company
15.8%
Market median
-125422252% vs market
20202024
Equity ratio
0.3%
This company
38.2%
Market median
-99% vs market
20202024
Return on equity
-2680.6%
This company
18.4%
Market median
-14668% vs market
20202024
Net profit margin
-268059200.0%
This company
8.1%
Market median
-3309372940% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
358.54×
This company
0.62×
Market median
-57729% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PT Chief Executive Officer | Chief Executive Officer | 2011 |
| Former (1) | ||
RK Deputy Member | Deputy Member | 2017 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hammerhead Technology As
PRE CHINA HCV AS Board members of PRE CHINA HCV AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Karsten Smith | Deputy Member | 0 companies |
| Pål Torleif Raaum | Chief Executive Officer | 0 companies |
| Kai Vidar Moe | Chairman | 0 companies |
| Johannes Andersen | Board of Directors | 0 companies |
| Morten Sjoner Syrstad | Board of Directors | 0 companies |